1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269–76.
2. Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–50.
3. Raherison C, Girodet P-O. Epidemiology of COPD. Eur Respir Rev 2009; 18: 114, 213–221.
4. Ewig S. Community-acquired pneumonia. Epidemiology, risk, and prognosis. Eur Respir Mon 1997; 3: 13–35.
5. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA 1999; 281: 61–6.
6. Kaplan V, Angus DC, Griffin MF et al. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Cars Med 2002; 165: 766–72.
7. Almirall J, Mesalles E, Klamburg J et al. Prognostic factors of pneumonia requiring admission to the intensive care unit. Chest 1995; 107: 511-6.
8. Ruiz M, Ewig S, Torres A et al. Severe community-acquired pneumonia. Risk factors and followup epidemiology. Am J Respir Crit Care Med 1999; 160: 923–9.
9. Georges H, Leroy O, Vandenbussche C et al. Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. Intensive Care Med 1999; 25: 198–206.
10. Rello J, Catalàn M, Díaz E et al. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2002; 28: 1030–5.
11. Rello J, Bodi M, Mariscal D et al. Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 2003; 123: 174–80.
12. Ruiz de Oña JM, Gómez M, Celdràn J, Puente-Maestu L. Neumon_a en el paciente con enfermedad pulmonar obstructiva cr_nica. Niveles de gravedad y clases de riesgo. Arch Bronconeumol 2003; 39: 101–5.
13. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with communityacquired pneumonia. Eur Respir J 2006; 28: 346–51.
14. Rello J, Rodriguez A, Torres A et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006; 27: 1210–6.
15. Garcia-Vidal C, Ardanuy C, Tubau F et al. Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax 2010; 65: 77–81.
16. Merino-S_nchez M, Alfageme-Michavila I, Lima-_lvarez J. Prognosis in Patients With Pneumonia and Chronic Obstructive Pulmonary Disease Arch Bronconeumol 2005; 41: 607–11.
17. Баймаканова Г.Е., Зубаирова П.А., Авдеев С.Н., Чучалин А.Г. Особенности клинической картины и течения внебольничной пневмонии у пациентов с хронической обструктивной болезнью легких. Пульмонология. 2009; 2: 33–41.
18. Boersma WG, Sportel JH, Lowenberg A, Koeter GH. High prevalence of obstructive airways disease in hospitalized patients with community-acquired pneumonia: comparison of four etiologies. Clin Pulm Med 2005; 12: 291–6.
19. Mannino DM, Davis KJ, Kiri VA. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir Med 2009; 103: 224–9.
20. Marcy TW, Merril WW. Cigarette smoking and respiratory tract infection. Clin Chest Med 1987; 8: 381–91.
21. McCusker K. Mechanisms of respiratory tissue injury from cigarette smoking. Am J Med 1992; 93 (suppl. 1A): 18S–21S.
22. Sherman CB. The health consequences of cigarette smoking: pulmonary diseases. Med Clin North Am 1992; 76: 355–75.
23. Almirall J, Gonzalez CA, Balanzo X et al. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest 1999; 116: 375–9.
24. Crim C, Calverley PM, Anderson JA et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34: 641–7.
25. Sin DD, Tashkin D, Zhang X et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712–9.
26. Lange P, Vestbo J, Nyboe J. Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. Eur Respir J 1995; 8: 1694–8.
27. Gau JT, Acharya U, Khan S et al. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr 2010; 10: 45.
28. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–89.
29. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144–9.
30. Wedzicha JA, Calverley PMA, Seemungal TA et al.; for the INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19–26.
31. Ferguson GT, Anzueto A, Fei R et al. Effect of fluticasone propionate/salmeterol (250/50 mg) or salmeterol (50 mg) on COPD exacerbations. Respir Med 2008; 102: 1099–108.
32. Anzueto A, Ferguson GT, Feldman G et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD 2009; 6: 320–329.
33. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997; 278: 1440–5.
34. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162–6.
35. Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010; 104: 246–52.
36. Drummond MB, Dasenbrook EC, Pitz MW et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease. A systematic review and meta-analysis. JAMA 2008; 300: 2407–16.
37. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease. A meta-analysis. Arch Intern Med 2009; 169: 219–29.
38. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting b-agonists and inhaled corticosteroids vs long-acting b-agonists monotherapy for stable COPD. A systematic review. Chest 2009; 136: 1029–38.
39. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; 4: CD006829.
40. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; 4: CD003794.
41. Page JA. Two cases of fulminating pneumonia in patients on hormone therapy. Brit Med J 1954; 1: 1334–5.
42. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheumatism 2006; 54: 628–34.
43. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. A systematic review and meta-analysis. Arch Intern Med 1999; 159: 941–55.
44. Welte T. Inhaled corticosteroids in COPD and the risk of pneumonia. Lancet 2009; 374: 668–70.
45. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007; 370: 786–96.
46. von Baum H, Welte T, Marre R et al., for THE CAPNETZ STUDY GROUP. Community-acquired pneumonia through enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors. Eur Respir J 2010; 35: 598–615.
47. Ko FWS, Ip M, Chan PKS et al. A one-year prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD and concomitant pneumonia. Respir Med 2008; 102: 1109–16.
48. Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 2007; 101: 2139–44.
49. Hogg JC, Chu FS, Tan WC et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007, 176: 454–9.
50. Diamond G, Legarda D, Ryan LK. The innate immune response of the respiratory epithelium. Immunol Rev 2000, 173: 27–38.
51. MacRedmond R, Greene C, Taggart CC et al. Respiratory epithelial cells require Toll-like receptor 4 for induction of human beta-defensin 2 by lipopolysaccharide. Respir Res 2005, 6: 116.
52. MacRedmond RE, Greene CM, Dorscheid DR et al. Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke. Respir Res 2007, 8: 84.
53. Esmailpour N, Hogger P, Rohdewald P. Binding of glucocorticoids to human nasal tissue in vitro. Int Arch Allergy Immunol 2000; 122: 151–4.
54. Mortimer KJ, Tattersfield AE, Tang Y et al. Plasma concentrations of fl uticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction. Br J Clin Pharmacol 2007; 64: 439–44.
55. Ek A, Larsson K, Siljerud S, Palmberg L. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy 1999; 54: 691–9.

С.Н.Авдеев